lentiviral vectors
Search documents
Preliminary results for the year ended 31 December 2025
Globenewswire· 2026-03-26 11:00
A year of strategic execution, strong revenue growth and positive Operating EBITDA Strong 2025 financial performance; revenues at upper end of guidance, with full year Operating EBITDA profitability achieved: Revenue growth of 33% to £170.9 million (CC) (FY 2024: £128.8 million) Operating EBITDA profit of £8.1 million (CC) (FY2024: £(15.3) million), driven by revenue growth and increasing focus on operating costs, and including one-off gain from the acquisition of the Durham, North Carolina (NC) facility.Un ...